Skip to content

Study · Not a test of the peptide alone · 1989

2 results

[Thymalin in the combined treatment of patients with chronic lympholeukemia].

Babenko TF, Antonenko VT, SkuratovskiUi MF

Vrachebnoe delo1 Mar 1989

PMID2750120 (opens in a new tab)PepBankPUB-02750120
Publisher pageAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Thymalin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymalin.

  1. 01HumanNot a test of Thymalin aloneNon-randomized trialEfficacy outcome

    In patients with B-variant chronic lympholeukemia, complex treatment containing thymalin improved lymphoid cell functional activity.

    In plain wordsIn chronic lympholeukemia patients, complex treatment containing thymalin improved lymphoid cell function.

    Peptide
    Thymalin
    Outcome
    IncreaseLymphoid cell functional activity
    Study

    n: not reported in source

    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    It was established that use of thymalin in patients with chronic lympholeukemia favoured improvement of the functional activity of lymphoid cells, reduced the time of reaching clinico-hematological remission.
    1 context sentence
    Summary · context
    Clinico-immunologic indices were studied in patients with the B-variant of chronic lympholeukemia (Stage II) under conditions of inclusion of thymalin in the complex treatment.

    In this study, Thymalin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymalin.

  2. 02HumanNot a test of Thymalin aloneNon-randomized trialEfficacy outcome

    In patients with B-variant chronic lympholeukemia, complex treatment containing thymalin reduced time to clinico-hematological remission.

    In plain wordsIn chronic lympholeukemia patients, complex treatment containing thymalin reduced the time to clinical and blood remission.

    Peptide
    Thymalin
    Outcome
    DecreaseTime to clinico-hematological remission
    Study

    n: not reported in source

    Outcome group
    Cancer treatment response · Cancer

    Source sentences

    Summary
    It was established that use of thymalin in patients with chronic lympholeukemia favoured improvement of the functional activity of lymphoid cells, reduced the time of reaching clinico-hematological remission.
    1 context sentence
    Summary · context
    Clinico-immunologic indices were studied in patients with the B-variant of chronic lympholeukemia (Stage II) under conditions of inclusion of thymalin in the complex treatment.

    In this study, Thymalin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymalin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.